Birnam Oak Advisors’s Cidara Therapeutics CDTX Stock Holding History

Birnam Oak Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-41,414	Closed	-$9.15M	–	40
2025 Q4	$9.15M	Buy	+41,414	New	+$6.69M	2.05%	14

Birnam Oak Advisors's CDTX Position: Q1 2026 in Review

Birnam Oak Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 41,414 shares — an estimated $9.15M sold.

Birnam Oak Advisors first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $9.15M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Birnam Oak Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Birnam Oak Advisors sold 41,414 Cidara Therapeutics shares in Q1 2026, an estimated $9.15M.
Birnam Oak Advisors first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Birnam Oak Advisors's Cidara Therapeutics position peaked at $9.15M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Birnam Oak Advisors's 13F filing for Q1 2026, filed 12 May 2026.